samedan logo
 
 
 
spacer
home > ebr > autumn 2021 > richter-helm – the cdmo to match your needs
PUBLICATIONS
European Biopharmaceutical Review

Richter-Helm – The CDMO to Match Your Needs

As the pharmaceutical and biotechnology industries continue to grow, they are accompanied by an increasing number of biopharmaceutical drug candidates, and a strong interest in bringing products to market quickly. The COVID-19 pandemic pushed demand and growth to the next level. Additionally, the biotech CDMO business sector is anticipated to develop. Richter-Helm, as a leading CDMO, reacts to this time-to-market pressure and the market’s need for specialised CDMO services with the expansion of its biomanufacturing facility. Adding a new microbial manufacturing facility to Richter-Helm’s Bovenau location in Germany will enable the company to maintain short timelines while increasing productivity.

Richter-Helm is a successful and progressive contract manufacturer with more than 30 years of experience. The expansion of the Bovenau biopharma production capacity will strengthen Richter-Helm’s position in the market and fulfil customers’ expectations. Construction of the new facility is expected to be completed within the next two years.

There is a broad range of approaches to produce biopharmaceuticals. Microbial-derived products, made by Richter-Helm, include a variety of product classes including therapeutic proteins and peptides, antibody formats (e.g., VHH), bacterial vaccines, and plasmid DNA (pDNA). With the addition of two highly flexible production chains with capacities of 300L and 1,500L, and fully separated flows, the new facility increases capacities for further and new projects of all the biopharmaceuticals listed above. The midstream and downstream operations will be executed in suites in the same building. In a variety of ways, individual bioreactors and suites can be arranged variably to offer multiple combinations for any manufacturing process or equipment – making it easy to adapt to bespoke/specific needs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Thilo Kamphausen, Director of Business Development
+49 (4331) 1230 – 451
t.kamphausen@richter-helm-biologics.eu

Dr Kai Pohlmeyer, Managing Director
+49 (40) 55290 – 430
k.pohlmeyer@richter-helm-biologics.eu

Richter-Helm BioLogics GmbH & Co.
KG Suhrenkamp 59 22335 Hamburg, Germany
+49 (0)40 / 55 290 - 801
spacer
Dr Thilo Kamphausen
spacer
spacer
spacer
Dr Kai Pohlmeyer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG ‘Makes it Better’

ACG is consolidating its founding values of caring, collaboration and progressiveness in a comprehensive re-brand. As one of the world's leading suppliers of fully integrated solutions to the global pharmaceutical and nutraceutical industry, ACG is taking this opportunity to share the message at the heart of its operation - ‘Make it Better’
More info >>

White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement